New Treatment of Alopecia Areata

NCT05594316 | Completed

• 1 other identifier: hossam pulse
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 2

Brief Summary

Abstract: Alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss. Methods: our study included 40 patients from may 2019 to july 2022 diagnosed clinically, dermatoscopically and pathologically as alopecia areata Data were enrolled from department of dermatology and venereology, Al-Hussein hospital.

Conditions

Alopecia Areata

Keywords

alopecia areata AA

Outcome Measures

Primary Outcomes (7)

• Mac Donald Hull and Norris grading system

  regrowth of vellus hair, regrowth of sparse pigmented terminal hair, regrowth of terminal hair with patches of alopecia and regrowth of terminal hair on scalp.

  4 weeks after the end of treatment

• Scoring of texture of regrown hair

  Fine vellus hair, Intermediate hair,Normal coarse hair

  after each session and 4 weeks after the end of treatment

• Scoring of pigmentation of regrown hair

  Partially pigmented, Moderately pigmented, Normally pigmented

  after each session and 4 weeks after the end of treatment

• Scoring for density of hair regrowth

  No hair growth, 1%-25% growth, 26%-50% growth, 51%-75% growth and 76%-100% growth

  after each session and 4 weeks after the end of treatment

• Scoring of overall response at the end of the study

  No response, Minimal response, Moderate response, Good response and Excellent response

  after each session and 4 weeks after the end of treatment

• histopathological changes

  appearance of lymphocytes around hair follicle, appearance of new blood vessels and size of thickness of hair follicles

  after each session and 4 weeks after the end of treatment

• trichoscopic parameters

  determine exclamation mark hairs, black dots, yellow dots and broken hairs

  after each session and 4 weeks after the end of treatment

Study Arms (1)

single group

OTHER

Trichloroacetic acid

Drug: Trichloroacetic acid

Interventions

Trichloroacetic acid DRUG

5\. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.

single group

Eligibility Criteria

• Age: 16 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Alopecia areata multilocularis and alopecia totalis. Age from 16-60 years old. Ophiasis pattern alopecia areata.

You may not qualify if:

• Age less than 16 and more than 60years old. Alopecia areata of the face.
• Patient under treatment.

Sponsors & Collaborators

• Al-Azhar University: lead

Study Sites (2)

Al-Azhar university, faculty of medicine

Cairo, Egypt

Location

Al-Azhar university

Cairo, Egypt

Location

MeSH Terms

Conditions

Alopecia Areata

Interventions

Trichloroacetic Acid

Condition Hierarchy (Ancestors)

Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Chloroacetates; Acetates; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Hydrocarbons, Chlorinated; Hydrocarbons, Halogenated; Hydrocarbons

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assisstant lecturer of dermatology,venerology and andrology

Study Record Dates

• First Submitted: October 19, 2022
• First Posted: October 26, 2022
• Study Start: May 1, 2019
• Primary Completion: August 1, 2022
• Study Completion: October 19, 2022
• Last Updated: October 26, 2022

Record last verified: 2022-10

Locations

EG (2)